New Drug Approvals

Home » Uncategorized » TROXACITABINE троксацитабин , تروكساسيتابين , 曲沙他滨 ,

TROXACITABINE троксацитабин , تروكساسيتابين , 曲沙他滨 ,



Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 


Recent Posts

Blog Stats

  • 4,108,527 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,766 other followers

add to any




CAS 145918-75-8

  • Molecular FormulaC8H11N3O4
  • Average mass213.191 Da
2(1H)-Pyrimidinone, 4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-

Hmd-cytosine; NCGC00183848-01; Beta-L-Dioxolane-cytidine; 4-amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one; 2R(-)-cis-Hmd-cytosine, (-)-ODDC

Troxacitabine.pngChemSpider 2D Image | Troxacitabine | C8H11N3O4


Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.[1]

Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.

Investigated for use/treatment in leukemia (myeloid).


WO 9218517

Inventors Yung-Chi Cheng, Chung K. Chu, Hea O. Kim, Kirupathevy Shanmuganathan
Applicant Yale University, The University Of Georgia Research Foundation, Inc.


WO 2016030335


WO 2016030335




Qu sand gemcitabine (4-amino -1 – [(2S, 4S) -2- ( hydroxymethyl) -1,3-dioxolan-4-yl] pyrimidin-2-one, Troxacitabine, Troxatyl (TM) ) Is an anti-tumor cytidine analogue developed by Yale University. In a multi-year Phase I / II clinical study in the United States, tacitabine was administered alone or mixed with other chemotherapeutic agents in a variety of dosage regimens, treating more than 825 patients with multiple solid tumors or blood Malignant tumor patients. In particular, tricatadine has the ability to inhibit the growth of hepatitis B virus and anti-hepatoma cells.
Chinese Patent Application No. 201310275643.2 discloses a method for the synthesis of tricatadine, which uses a L-menthol ester of dihydroxyacetic acid as a raw material and undergoes condensation reaction with hydroxyacetaldehyde, and then the hydroxyl group is halogenated to obtain a halide , The halide is coupled with cytosine to obtain the coupling, and the conjugate is reduced to obtain tricatadine. However, the present inventors have found that the method requires a four-step reaction, such as condensation, halogenation, coupling and reduction, which is required to be carried out in different reaction systems. The steps are long and cumbersome, and in particular, the intermediate product is required to be separated and replaced Containers, and not suitable for amplification, it is not suitable for industrial production.
the present invention provides a process for the synthesis of a compound of formula III, wherein the synthesis reaction formula is as follows:
Example 1 Synthesis of tricatadine
The synthetic route is as follows:
Step 1: Preparation of Formula II
18.0 g of methylene chloride was added to the reaction kettle, and the mixture of the formula I was homogeneously added. After the temperature was lowered to 0 ± 3 ° C under the protection of nitrogen, 1.5 g of trimethyl iodosilane was slowly added; (V / v), and R f = 0.5 at the point of disappearance). The reaction was carried out under nitrogen atmosphere for 2.5 ± 0.5 hours until the reaction was complete (sampling TLC test: developing solvent: petroleum ether: ethyl acetate = 4: 1 (v / v) Subsequently, the temperature of the autoclave was kept at 0 ± 3 ° C, and 3.64 g of hexamethyldisilazane and 1.15 g of N 4 -acetyl cytosine were slowly added dropwise . After the completion of the addition, the temperature of the control kettle was 0 ± 3 ℃, and the reaction was carried out under the protection of nitrogen for 3.5 ± 0.5 hours until the reaction was complete (sampling TLC test: developing agent: petroleum ether: ethyl acetate = 4: 1 (v / v), R F = 0.2 points disappear).
Then, the temperature was maintained at 22 ± 3 ° C, and 10 %% (w / w) aqueous sodium thiosulfate solution was slowly added dropwise. After adding 5 g of aqueous sodium thiosulfate solution, 0.5 g of diatomaceous earth was added, hour. Filter, filter cake washed with methylene chloride 3 times, filter cake collection stand-by. The filtrate and the washing liquid were combined into the kettle, the aqueous phase and the organic phase were separated. The organic phase was washed once with 11.3 g of saturated brine. The organic phase was separated and dried overnight with anhydrous sodium sulfate to remove the water. Remove the sodium sulfate solid, the filtrate into the rotary evaporator, steaming temperature does not exceed 45 ℃, until the end of distillation. The residue obtained by steaming was transferred to a reaction vessel, 11.2 g of acetone and 18.5 g of isopropyl acetate were added, and the mixture was heated to reflux (68 ± 3 ° C) and stirred for 1 hour. Within 2.5 ± 0.5 hours, slowly cool down until the kettle temperature is 22 ± 3 ° C. The filter was filtered in a vacuum oven at about 40 ° C and dried overnight under vacuum to give a white solid (formula II).
The diatomaceous earth cake obtained by the above-mentioned filtration was transferred to a reaction vessel, heated to 27 ± 3 ° C, 18.0 g of methylene chloride was added, and the mixture was stirred and stirred for 2 hours. The filtrate was filtered and the filtrate was transferred to a rotary evaporator. The steaming temperature did not exceed 45 ° C until the distillation was completed. The crude solid obtained by steaming (the crude product of formula II) and the white solid used in the previous step were combined and transferred to a reaction kettle, and an isopropyl acetate: acetone = 3: 2 (v / v) mixed solvent was added (1 g of crude (13.3 g of isopropyl acetate + 7.9 g of acetone) was added and heated to reflux (68 ± 3 ° C), and the mixture was stirred for 1 hour. In 2.5 ± 0.5 hours, slow down to the kettle temperature of 22 ± 3 ℃. Quickly filter the filter cake with cold acetone 1.5g once. The filter cake was placed in a vacuum oven at about 40 ° C and dried overnight under vacuum to give the formula II.
Step 2: Preparation and purification of formula III
Take the type II boutique 1g added to the four bottles, add methanol 5.0g, stir the solid dispersed evenly. And 0.045 g of sodium methoxide was weighed, and the mixture was added to 0.135 g of methanol and stirred to dissolve sodium methoxide. The methanol solution of sodium methoxide was added dropwise to a four-necked flask. The incubation was carried out at 22.5 ± 2.5 ° C for 1 hour until the reaction was complete (sampling TLC: developing solvent: dichloromethane: methanol = 4: 1 (v / v) and R f = 0.8).
After completion of the reaction, the pH of the system was adjusted to 6.5 ± 0.5 with ice acetic acid under ice bath. And then adding 200-300 mesh silica gel (available from Qingdao Ocean Chemical Plant) 10 g of sand, filling the column, the column chromatography, which was dichloromethane: methanol = 4: 1 (v / V), collecting the fraction containing tricatropa, and steaming to dryness. The steamed solid was transferred to a three-necked flask, 3.0 g of absolute ethanol was added, and the mixture was uniformly dispersed (suspended) and heated to 78 ± 2 ° C for 0.5 hour. After completion of the reflux, slowly (2.5 ± 0.5 hours) was cooled to room temperature and stirred at room temperature for 12 hours. Continue to cool down to 2.5 ± 2.5 ℃, at this temperature holding 4.5 ± 0.5 hours. Filter, filter cake with 1.0g cold ethanol washing once, thoroughly filter, the filtrate abandoned. The filter cake was transferred to a vacuum oven and dried at 38 ± 2 ° C until constant weight to obtain a purity of the formula III.
The above method can be equal to the proportion of stable amplification, for example, can be directly amplified about 60 to 180 times, that is, I feed 61.7g ~ 185.97g (other reactants equal ratio increase), after amplification of the final product (formula III) HPLC detection purity To 99.3% ~ 99.8%, the yield of 65 ~ 85%, fully meet the tricatitabine medicinal industrial needs.


CN 104861067


CN 105503838


In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs
Journal of medicinal chemistry (2007), 50, (9), 2249-53.

J. Med. Chem., 2007, 50 (9), pp 2249–2253
DOI: 10.1021/jm0612923

Abstract Image

l-1,3-Dioxolane-cytidine, a potent anticancer agent against leukemia, has limited efficacy against solid tumors, perhaps due to its hydrophilicity. Herein, a library of prodrugs were synthesized to optimize in vitro antitumor activity against non-small cell lung cancer. N4-Substituted fatty acid amide prodrugs of 10−16 carbon chain length demonstrated significantly improved antitumor activity over l-1,3-dioxolane-cytidine. These in vitro results suggest that the in vivo therapeutic efficacy of l-1,3-dioxolane-cytidine against solid tumors may be improved with prodrug strategies.


  • Kim, Hea O.; Schinazi, Raymond F.; Shanmuganathan, Kirupathevy; Jeong, Lak S.; Beach, J. Warren; Nampalli, Satyanarayana; Cannon, Deborah L.; Chu, Chung K.
  • From Journal of Medicinal Chemistry (1993), 36(5), 519-28.


  • Jin, Haolun; Tse, Allan Tse; Evans, Colleen A.; Mansour, Tarek S.; Beels, Christopher M.; Ravenscroft, Paul; Humber, David C.; Jones, Martin F.; Payne, Jeremy J.; Ramsay, Michael V. J.
  • From Tetrahedron:  Asymmetry (1993), 4(2), 211-14


  • Belleau, Bernard R.; Evans, Colleen A.; Tse, H. L. Allan; Jin, Haolun; Dixit, Dilip M.; Mansour, Tarek S.
  • From Tetrahedron Letters (1992), 33(46), 6949-52.


J. Med. Chem. 1992,35,1987-1995 Asymmetric Synthesis of 1,3-Dioxolane-Pyrimidine Nucleosides and Their Anti-HIV Activity

Image result for TROXACITABINEReferences

  1. Jump up^ Vose, Julie M.; Panwalkar, Amit; Belanger, Robert; Coiffier, Bertrand; Baccarani, Michele; Gregory, Stephanie A.; Facon, Thierry; Fanin, Renato; Caballero, Dolores; Ben-Yehuda, Dina; Giles, Francis (2007). “A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma”. Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578.
  1. Lee CK, Rowinsky EK, Li J, Giles F, Moore MJ, Hidalgo M, Capparelli E, Jolivet J, Baker SD: Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2158-65. [PubMed:16609029 ]
  2. Quintas-Cardama A, Cortes J: Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2007 Apr;16(4):547-57. [PubMed:17371201 ]
  3. Swords R, Giles F: Troxacitabine in acute leukemia. Hematology. 2007 Jun;12(3):219-27. [PubMed:17558697 ]
  4. Orsolic N, Giles FJ, Gourdeau H, Golemovic M, Beran M, Cortes J, Freireich EJ, Kantarjian H, Verstovsek S: Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. Br J Haematol. 2004 Mar;124(6):727-38. [PubMed:15009060 ]
  5. Boivin AJ, Gourdeau H, Momparler RL: Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. Cancer Invest. 2004;22(1):25-9. [PubMed:15069761 ]
  6. Kim TE, Park SY, Hsu CH, Dutschman GE, Cheng YC: Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines. Mol Pharmacol. 2004 Aug;66(2):285-92. [PubMed:15266019 ]
1 to 3 of 3
Patent ID Patent Title Submitted Date Granted Date
US7927613 Pharmaceutical co-crystal compositions 2003-09-11 2011-04-19
US7790905 Pharmaceutical propylene glycol solvate compositions 2003-12-29 2010-09-07
CAS Number
PubChem CID
Chemical and physical data
Formula C8H11N3O4
Molar mass 213.19 g/mol
3D model (Jmol)

//////////////TROXACITABINE, троксацитабин , تروكساسيتابين , 曲沙他滨 , Hmd-cytosineM,  NCGC00183848-01, Beta-L-Dioxolane-cytidine,   2R(-)-cis-Hmd-cytosine, (-)-ODDC

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Follow New Drug Approvals on

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,766 other followers


DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →



Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: